Singapore Clinical Research Institute (SCRI)

SCRI has identified a partnership that would significantly augment its capability and cement its ability to be a coordinating centre of clinical trials in the ASEAN region.

The partnership is with Choice Pharma, who bring with them a complementary suite of expertise and experience in consultancy, clinical research, drug safety, regulatory affairs and communications. With headquarters in the UK and a firm presence in the US, Switzerland, Dubai, Singapore, Taiwan, Korea and China, Choice Pharma supports biotech and pharmaceutical companies around the world at every stage of the product lifecycle, from first-in-man studies to product launches and beyond.

Through the combination of our respective strengths, expertise and presence in North Asia, partnership with Choice Pharma provides an immediate expansion of presence in the Asia Pacific Region. This in turn enhances SCRI's reach as well as its capability and capacity to  conduct  multi-site clinical research in the region.

For more information on Choice Pharma, please visit www.choicepharma.com